Huberman LabJournal Club with Dr. Peter Attia | Metformin for Longevity & The Power of Belief Effects
At a glance
WHAT IT’S REALLY ABOUT
Metformin Myths, Nicotine Beliefs: Attia & Huberman Redefine Longevity Science
- Andrew Huberman and Peter Attia host a live ‘journal club’ to dissect two papers: a large epidemiological reassessment of metformin and a human neuroimaging study on belief‑driven nicotine effects.
- Attia walks through how the new Danish registry data challenge a famous 2014 study that suggested metformin users with type 2 diabetes outlive non‑diabetics, underscoring the limits of observational epidemiology and his own reasons for stopping metformin.
- Huberman presents a placebo/belief paper showing that smokers’ brains respond in a dose‑dependent way to how much nicotine they think they vaped, despite all receiving the same low dose, revealing that expectations can scale neural and behavioral drug effects.
- Across both discussions they model how to read scientific papers, think statistically, and separate mechanistic plausibility, biomarkers, and hype from data that meaningfully inform health and longevity decisions.
IDEAS WORTH REMEMBERING
5 ideasThe best current epidemiology does *not* support metformin as a longevity drug in healthy, non‑diabetic people.
The 2014 Bannister study found that type 2 diabetics on metformin had a ~15% lower all‑cause mortality than matched non‑diabetics. Attia explains that result relied on “informative censoring”: diabetics who worsened and left metformin (often by dying or needing stronger drugs) were removed from analysis, biasing survival upward. A newer Danish registry study (Keys et al.) with ~500,000 people, discordant twins, and sensitivity analyses (with and without censoring) showed diabetics on metformin still had *higher* mortality (hazard ratios ~1.3–2.1) than non‑diabetics. Metformin may still help diabetics versus *no* treatment, but there’s no credible evidence yet that it extends life beyond normal in healthy people.
Epidemiologic studies can look very convincing but are inherently limited by confounding and model choices.
Attia walks through Table 1 of the Keys paper to show how, even after matching age, sex, BMI, etc., medication use diverged massively: far more diabetics were on lipid‑lowering, antihypertensive, antiplatelet, and other drugs. Statistical adjustments (three levels of models) reduce but do not erase these differences, and you can never fully correct for unmeasured behaviors (diet quality, exercise, health consciousness). Large sample size and long follow‑up increase power, but without randomization you can’t cleanly isolate the causal effect of metformin.
Lifestyle interventions remain the foundation for glucose control and longevity; drugs are adjuncts, not substitutes.
Attia emphasizes that the primary causes of insulin resistance and type 2 diabetes are energy imbalance, low physical activity, excess ectopic fat (fat in muscle, liver, pancreas), poor sleep, and chronic stress/hypercortisolemia. The earliest warning sign is *elevated insulin* with normal glucose, not glucose itself. Exercise (especially consistent, higher‑volume activity) and adequate sleep dramatically improve insulin sensitivity, sometimes cutting glucose disposal deficits in half within a week of better sleep. He still uses metformin for insulin‑resistant patients but does not see it as a blanket longevity tool for fit, insulin‑sensitive people.
Metformin has meaningful mechanistic downsides for performance and possibly hypertrophy, which matter in cost–benefit decisions.
Metformin weakly inhibits mitochondrial complex I, shifting fuel partitioning and raising basal lactate. When Attia started doing lactate‑based zone 2 training, his fasted resting lactate on metformin was ~1.6 mmol/L instead of <1.0 mmol/L, suggesting he was effectively slightly anaerobic at baseline. That, plus data that metformin may blunt strength and hypertrophy gains, pushed him to stop after years of use. For athletes or people prioritizing performance and muscle mass, those tradeoffs may outweigh any speculative geroprotective benefit.
Beliefs about drug dose can scale real brain responses in a dose‑dependent manner, not just subjective feelings.
In the Gu et al. nicotine study, experienced smokers vaped the *same* low nicotine dose but were told it was low, medium, or high. Their subjective ratings matched the instructions (they “felt” low/medium/high), but critically, fMRI showed that activity in thalamic–ventromedial prefrontal cortex circuits—central to attention and learning—scaled with the believed dose. The more nicotine they *thought* they got, the stronger the circuit activation, even though blood nicotine levels were essentially identical. This goes beyond classic placebo (drug vs no drug) to show true dose‑response in belief effects at the neural level.
WORDS WORTH SAVING
5 quotesThe Keys paper makes it undeniably clear that in that population, there was no advantage offered by metformin that undid the disadvantage of having type 2 diabetes.
— Peter Attia
We have to walk around with an appropriate degree of humility about what we know and what we don’t know.
— Peter Attia
What we are told about the dose of a drug changes the way that our physiology responds to the dose of the drug.
— Andrew Huberman
Your brain is a prediction‑making machine, and one of the most important pieces of data it uses is your beliefs about what things do to you.
— Andrew Huberman
Without good biomarkers of aging, we’re basically flying blind on most geroprotective interventions.
— Peter Attia
High quality AI-generated summary created from speaker-labeled transcript.
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome